Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

a composite of death, myocardial infarction (MI), urgent target vessel revascularization (TVR) or recurrent ischemia at 30 days.  

Previously presented data from RADAR (AHA, November 2010) confirmed that pegnivacogin dosed at 1mg/kg reproducibly resulted in near complete inhibition of FIXa in an ACS population.  The latest RADAR results showed that ACUITY major bleeding following immediate sheath removal exhibited a dose response with bleeding rates decreasing with increasing levels of reversal.  Rates of bleeding were lower in the 75% and 100% reversal arms than heparin.  In addition, the incidence of ischemic events was lower in REG1 treated patients compared with those treated with heparin.  

Adverse events (AEs) other than bleeding and ischemic events were rare and evenly distributed among the arms of the study.  Three patients, clustered late in the trial and in Europe, had allergic-like reactions shortly after receiving pegnivacogin.  Characterization of these reactions is ongoing.  

"We are thrilled by the results of RADAR and the groundbreaking advance in anticoagulant therapy that they foretell.  It is now clear that control matters.  REG1 uniquely has shown the promise of simultaneously reducing ischemia and bleeding in comparison to heparin," said Dr. David J. Mazzo, President and CEO of Regado Biosciences, Inc.  He added, "The results of the RADAR trial solidly support Phase 3 development of REG1 in the broader ACS population.  Regado plans to move forward in this indication as well as in a parallel indication of open heart surgery."  

"The Phase 2b RADAR results suggest that high intensity FIXa inhibition with active control may ultimately represent a potential treatment option for addressing both ischemic and bleeding endpoints for patients who require short term anticoagulation in acute care settings," said John H. Alexander, MD, MHS, FACC of the Duke Clinica
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... BerGenBio AS ("BerGenBio" or the ... has appointed Hilde Furberg and Dr ... of Directors, effective immediately. Hilde Furberg ... and biotech and is currently Senior Vice President Rare ... role was Vice President and General Manager of Nordic ...
(Date:8/31/2015)...  DICOM Grid,  the #1 medical image exchange ... as a semifinalist for a Minnie award for ... are sponsored by Auntminnie.com, a comprehensive community website ... imaging industry.  Since 1999, the "Minnies" have provided ... contributions of their peers. Nominations are made by ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2DG Suite Nabs "Minnies" Nomination for "Best New Radiology Software" 2Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2
(Date:9/1/2015)... ... September 01, 2015 , ... Splashtop Inc. , the ... Support , a solution optimized for MSPs and IT professionals looking for a ... and inadequate customer services of existing remote support solution, many MSPs and ITs ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... a top-five hospital by U.S. News & World Report, to provide breaking news ... , Editorial and marketing groups within OncLive, which provides oncologists resources and information?they ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding ... since its inception more than 35 years ago. A pilot program begun by the ... - and, not just those intent on pursuing careers in these fields. The program ...
(Date:9/1/2015)... York, New York (PRWEB) , ... September 01, 2015 , ... ... Zecurion Zlock Mac , its groundbreaking new version of endpoint DLP developed specifically ... of Zlock Mac, in which more than 100 IT and information security professionals had ...
(Date:9/1/2015)... ... September 01, 2015 , ... Agriculture innovation, urban farming, local food access, and ... be discussed at Seedstock’s 4th Annual Sustainable Agriculture Conference : “Innovation and the ... , In addition to keynotes Pierre Sleiman, founder and CEO of Go Green Agriculture, ...
Breaking Medicine News(10 mins):Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:Zecurion Announces Endpoint Security for Mac 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 2Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 3Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 4Health News:Experts in Urban and Local Food Systems Development to Address Seedstock Sustainable Agriculture Conference Nov. 3-4 Discounted ticket sales end Sept. 4 5
... , THURSDAY, July 29 (HealthDay News) -- Doctors and patients ... comes to what patients believe about their illnesses, including to ... best way to manage the problem, new research shows. ... communication, researchers said. Patients who were "active participants" in their ...
... prostate cell that has been largely ignored by cancer researchers ... studies by Howard Hughes Medical Institute (HHMI) scientists and their ... colleagues at the University of California, Los Angeles (UCLA) found ... in the prostate gland. Their studies, which were unveiled in ...
... how individual connections between brain cells remain diverse and "fit" ... journal Neuron , a new study led by Dr. ... Aviv University describes what makes some memories stick. The ... in the brain, which could be the main factor in ...
... two rivers in southern Alberta are likely the cause of ... Calgary who have published results of their study in the ... unique about our study is the huge geographical area we ... that have the potential to harm fish were present ...
... HealthDay Reporter , THURSDAY, July 29 (HealthDay News) ... the middle class? Will panels decide what care very sick, ... crowd. A new Harris Interactive/HealthDay poll shows confusion still ... law by President Barack Obama back in March. More ...
... This release is available in Spanish . ... an important role in keeping the immune system healthy. Now, ... cell-culture study showing that white button mushrooms enhanced the activity ... the United States, white button mushrooms represent 90 percent of ...
Cached Medicine News:Health News:Doctors, Patients Rarely on Same Page 2Health News:Doctors, Patients Rarely on Same Page 3Health News:A new ground zero for prostate cancer 2Health News:A new ground zero for prostate cancer 3Health News:Memory's master switch 2Health News:Memory's master switch 3Health News:Gender-bending fish on the rise in southern Alberta 2Health News:Americans Still Confused About Health Reform 2Health News:Americans Still Confused About Health Reform 3Health News:Americans Still Confused About Health Reform 4
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
... The 45° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
Medicine Products: